A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (NCT03149003)

Investigator: David Baskin, MD

Study Coordinator: Larisse Yewah Gwei

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03149003

Phone: 713.441.3834

Protocol Number: Pro00017715


This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.
More to Explore